TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22251482
Drug: FBS0701 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBS0701 at 29 mg/kg/d
Study: 19177255
Drug: Transdermal E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/NETA 50 microg/140 microg
Study: 11666126
Drug: Total triterpenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) at 120 mg daily
Study: 11666126
Drug: Total triterpenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) at 60 mg daily
Study: 9579130
Drug: Abdominal wall
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal wall injection of low-dose heparin
Study: 9579130
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb injection of low-dose heparin
Study: 28774885
Drug: MNP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNP with 5 mg iron (Fe group)
Study: 28774885
Drug: MNP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNP with 7.5 g GOS and 5 mg iron (FeGOS group)
Study: 23816760
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus carboplatin; S-1 at 80 mg/m²/day for 2 weeks, followed by 2 weeks of no treatment; Carboplatin at AUC 6 on day 8, repeated for 4-6 cycles of 28 days
Study: 16924046
Drug: 5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% fluorouracil cream applied twice daily for 3 weeks
Study: 16924046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 of 7 eligible patients who declined study-related treatment)
Study: 11167663
Drug: Moxonidine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.1, 0.2, 0.3 mg twice daily)
Study: 9042124
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (15 minutes before and after treatment)
Study: 2145654
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg almitrine
Study: 2145654
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg medroxyprogesterone
Study: 23122840
Drug: 1 IU
Normalized name: factor VIII 1 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 IU of oxytocin followed by an infusion of 2.5 UI×h(‐1)
Study: 23122840
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 20 IU oxytocin at a rate of 700 mUI×min(‐1) followed later by 10 UI×h(‐1)
Study: 23122840
Drug: 100μg bolus
Normalized name: sulfadimethoxine
DrugBank: Sulfadimethoxine (DB06150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100μg bolus dose of carbetocin
Study: 19054496
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravitreal triamcinolone acetonide (TA)
Study: 19054496
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg orbital floor triamcinolone acetonide (TA)
Study: 9006811
Drug: Extended-release gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release gemfibrozil (1200 mg/day) for 3 months
Study: 9006811
Drug: Regular gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular gemfibrozil (1200 mg/day) for 6 months
Study: 6376209
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg plus triamterene 50 mg
Study: 22295813
Drug: Distant acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distant acupuncture and nearby tuina therapy (30 treatments)
Study: 22295813
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate D, Tablet (orally for 12 weeks)
Study: 20814848
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg od
Study: 20814848
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg od
Study: 11896100
Drug: EU/5-FU (11.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU/5-FU (11.5 mg/m²/1.15 mg/m² twice daily for 28 days every 35 days)
Study: 11896100
Drug: 5-FU/LV (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV (425 mg/m²/20 mg/m² once daily for 5 days every 28 days)
Study: 27544544
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2000 IU daily from 26 to 28 weeks of gestation until childbirth)
Study: 17499406
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of quadrivalent HPV vaccine
Study: 11601954
Drug: Pharmacologic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatments
Study: 11601954
Drug: Nonpharmacologic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatments
Study: 22805291
Drug: Trametinib 2
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 2 mg once daily
Study: 28732813
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with Curcuma longa
Study: 28732813
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with Angelica sinensis
Study: 28732813
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with Panax ginseng
Study: 25109412
Drug: Immediate-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release guanfacine (4 mg)
Study: 25109412
Drug: Immediate-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release guanfacine (8 mg)
Study: 23294775
Drug: Fixed-dose design
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose design
Study: 21410033
Drug: Four-component intravenous
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-component intravenous lipid emulsion (LCT, MCT, Olive-oil and Fish-oil)
Study: 8546294
Drug: Droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1.25 mg) with morphine (1 mg.ml‐1)
Study: 8546294
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg) with morphine (1 mg.ml‐1)
Study: 8546294
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg.ml‐1) alone
Study: 6328297
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir
Study: 31250889
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g BCAA
Study: 31250889
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g BCKA
Study: 31250889
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g MILK
Study: 29879719
Drug: Nimodipine plus
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine plus Yufeng Ningxin tablets
Study: 22429354
Drug: Remifentanil (intravenous)
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (intravenous)
Study: 22429354
Drug: Clonidine (intravenous)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (intravenous)
Study: 20124231
Drug: IVIG, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG, 0.5 g/kg
Study: 12135030
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg budesonide CIR once daily
Study: 12135030
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg budesonide CIR b.i.d.
Study: 8578018
Drug: Roxithromycin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (low dose for a long period of time)
Study: 7468062
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 units every 12 hours for 10 days)
Study: 7468062
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + Dihydroergotamine (0.5 mg at the same intervals as heparin)
Study: 25927298
Drug: Biological measurements
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological measurements including hair and saliva samples.
Study: 23337477
Drug: lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide Autogel 60 mg
Study: 23337477
Drug: lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide Autogel 90 mg
Study: 23337477
Drug: lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lanreotide Autogel 90 mg (adjusted according to clinical responses)
Study: 12038945
Drug: Active lozenge
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active lozenge
Study: 2665802
Drug: Placebo therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapies
Study: 339214
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily atenolol (100 mg)
Study: 339214
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily atenolol (100 mg or 50 mg)
Study: 25304832
Drug: Preoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative physical activity intervention (PAI) for 6 weeks, including weekly individual face-to-face sessions with tailored instruction in behavioral strategies
Study: 19820017
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg anastrozole daily
Study: 16829029
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 mcg of selenomethionine daily)
Study: 11576045
Drug: Naloxone 10
Normalized name: naloxone 10 mg/0.11 mL nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 10 mg
Study: 3582483
Drug: Ketotifen syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen syrup 1 mg b.i.d. for 8 days
Study: 3582483
Drug: Aminophylline syrup
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline syrup 6 mg/kg
Study: 21445642
Drug: Inhaled sevoflurane
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sevoflurane (group S)
Study: 21445642
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (group P)
Study: 21445642
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (group M)
Study: 18159096
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and cilostazol (group I, n=141)
Study: 18159096
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (group II, n=139)
Study: 14610641
Drug: Ibandronate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (2 mg) injections every 3 months plus daily calcium supplements (500 mg)
Study: 14610641
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral alfacalcidol (1 microg) plus daily calcium supplements (500 mg)
Study: 3885173
Drug: Combination vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vindesine and cisplatin (DDP)
Study: 3885173
Drug: Single-agent vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent vindesine (DVA)
Study: 28671753
Drug: Strategy-A (glucose-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy-A (glucose-dependent therapies with a non-sulphonylurea OAM and a glucagon-like peptide-1 receptor agonist)
Study: 28671753
Drug: Strategy-B (non-glucose-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy-B (non-glucose-dependent therapies with sulphonylurea and insulin glargine)
Study: 25014995
Drug: Web-based ESRA-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based ESRA-C intervention delivered to patients' homes or to a tablet in clinic.
Study: 10793318
Drug: Pindolol augmentation
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol augmentation (2.5 mg x 3/d) with paroxetine (60 mg/d)
Study: 10793318
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation with paroxetine (60 mg/d)
Study: 8899094
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 1 week, then once daily for 3 weeks
Study: 8899094
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg twice daily for 1 week, then once daily for 3 weeks
Study: 6194757
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic therapy (sulbenicillin and amikacin) with S‐sulfonated gamma‐globulin (Group A)
Study: 6194757
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic therapy (sulbenicillin and amikacin) without S‐sulfonated gamma‐globulin (Group B)
Study: 31566309
Drug: Encorafenib, binimetinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib, binimetinib, and cetuximab (triplet-therapy group)
Study: 31566309
Drug: Encorafenib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib and cetuximab (doublet-therapy group)
Study: 23411644
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy of the neck region
Study: 19549306
Drug: Phytotherapeutic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapeutic combination treatment
Study: 15197195
Drug: GV (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV (gemcitabine 1000 mg/m(2) + vinorelbine 25 mg/m(2) on days 1 and 8 every 3 weeks)
Study: 15197195
Drug: GVP (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVP (gemcitabine 1000 mg/m(2) + vinorelbine 25 mg/m(2) + cisplatin 75 mg/m(2) on day 2 every 3 weeks)
Study: 15489869
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg intravenously every 8 h
Study: 15489869
Drug: Granisetron 10
Normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 10 microg/kg intravenously daily
Study: 10077963
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shockwave therapy (ESWT) with 250 impulses of 0.04 mJ/mm2
Study: 10077963
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with shock-wave impact inhibited by a neopren insert
Study: 10077963
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shockwave therapy (ESWT)
Study: 7235851
Drug: Treatment on
Normalized name: Canesten Clotrimazole Thrush Treatment Once (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment on a research unit
Study: 31793165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lixisenatide and insulin glargine
Study: 30876869
Drug: Low-dose fascia
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fascia iliaca compartment block (FICB)
Study: 28069051
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine plus basic treatment (steroids and 5-aminosalicylic acid)
Study: 28069051
Drug: Azathioprine plus
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine plus basic treatment (steroids and 5-aminosalicylic acid)
Study: 25090366
Drug: Telephone-administered supportive-expressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered supportive-expressive group therapy
Study: 23102179
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g ground cinnamon
Study: 19553931
Drug: PPAR-agonist treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR-agonist treatment
Study: 19553931
Drug: Non-PPAR drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PPAR drugs
Study: 17616069
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with 500 mg of sacharose ferric oxide (Venofer)
Study: 15015147
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein restriction (0.71 g x kg(‐1) fat‐free mass x d(‐1))
Study: 15015147
Drug: Ample American-style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ample American-style protein intake (1.67 g x kg(‐1) fat‐free mass x d(‐1))
Study: 9537309
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg zinc (n = 68)
Study: 9537309
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zinc (n = 71)
Study: 7702150
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural infusion of bupivacaine 0.2% with fentanyl 10 micrograms.ml‐1
Study: 7702150
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural infusion of bupivacaine 0.2% with fentanyl 10 micrograms.ml‐1
Study: 28404157
Drug: Weekly nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly nab-paclitaxel (100 mg/m2, on days 1, 8, and 15 of a 28-day cycle)
Study: 28404157
Drug: Nab-paclitaxel every
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel every 3 weeks (260 mg/m2, on day 1 of a 21-day cycle)
Study: 28404157
Drug: Weekly solvent-based
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly solvent-based paclitaxel (80 mg/m2, on days 1, 8, and 15 of a 28-day cycle)
Study: 25739878
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose measles-virus-based candidate vaccine (1.5 x 10^4 TCID50 per 0.05 mL)
Study: 25739878
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose measles-virus-based candidate vaccine (7.5 x 10^4 TCID50 per 0.25 mL)
Study: 25739878
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose measles-virus-based candidate vaccine (3.0 x 10^5 TCID50 per 1.0 mL)
Study: 25739878
Drug: Measles-virus-based candidate
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-virus-based candidate vaccine (all doses)
Study: 17415030
Drug: MIST Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIST Therapy plus standard of wound care
Study: 7473919
Drug: Human Growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Growth Hormone (HGH) administration
Study: 7473919
Drug: No Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Human Growth Hormone (Control)
Study: 31859245
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg belantamab mafodotin
Study: 31859245
Drug: 3.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 mg/kg belantamab mafodotin
Study: 25633544
Drug: REBT-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: REBT-based intervention (8 sessions weekly: 6 individual and 2 group sessions)
Study: 19995206
Drug: Refractive error
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractive error and posterior capsule opacification
Study: 11927223
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir 2000 mg four times daily for 90 days
Study: 11927223
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 200 mg four times daily for 90 days
Study: 9793814
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg plus droperidol 0.625 mg (Group OD)
Study: 9793814
Drug: droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.625 mg plus metoclopramide 10 mg (Group DM)
Study: 9793814
Drug: perphenazine 5
Normalized name: perphenazine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: perphenazine 5 mg (Group P)
Study: 8569644
Drug: Inhaled nedocromil
Normalized name: nedocromil Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nedocromil sodium 16 mg/day
Study: 8569644
Drug: Inhaled nedocromil
Normalized name: nedocromil Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nedocromil sodium 8 mg/day
Study: 2692894
Drug: Peripatellar methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripatellar methylprednisolone injection